Spero Therapeutics, Inc. — Director's Dealing 2021

Jan 6, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Spero Therapeutics, Inc. (SPRO)
CIK: 0001701108
Period of Report: 2021-01-04

Reporting Person: Smith Cynthia (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-04	Stock Option (right to buy)	$17.93	A	2629	Acquired	2031-01-04	Common Stock (2629)	Direct

Footnotes

F1: This stock option shall vest in four quarterly installments on the last day of each calendar quarter during the calendar year subject to the Reporting Person's continued service as a non-employee director.

F2: This stock option was issued to the Reporting Person, who elected to take stock options in lieu of $35,000 in cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation policy.